耐火性慢性咳に対するガバペンチン:ランダム化,ダブルブラインド,プラセボ対照試験
Nicole M Ryan1, Surinder S Birring, Peter G Gibson
1Priority Centre for Asthma and Respiratory Diseases, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia. nicole.ryan@newcastle.edu.au
Lancet (London, England)
|September 7, 2012
まとめ
ガバペンチンは,耐性慢性咳を効果的に治療し,生活の質を大幅に改善します. この神経調節器はよく耐受され,中央の感受性がこの状態で重要な役割を果たしていることを示唆しています.
科学分野:
- 肺内科 肺内科 肺内科
- 神経学 神経学とは
- 臨床薬理学 臨床薬理学とは
背景:
- 耐火性慢性咳は,生活の質を著しく損なう.
- 中心反射感受化が鍵となるメカニズムであり,神経疾患の痛みと似ています.
- ガバペンチンなどの神経調節剤は,潜在的な治療法です.
研究 の 目的:
- 耐火性慢性咳に対するガバペンチンの有効性と耐容性を確立するために.
- ガバペンチンの咳特異的な生活の質への影響を調査する.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照試験.
- 慢性咳 (>8週間) を有する成人は,ガバペンチン (最大1800mg/日) またはプラセボを10週間投与された.
- プライマリエンドポイント:レイスター咳問卷 (LCQ) 8週後のスコアの変化.
主要な成果:
- ガバペンチンは,プラセボと比較して,咳特有の生活の質を有意に改善しました (p=0.004).
- 治療に必要な数は3.58でした.
- 副作用 (吐き気,疲労) はガバペンチンでより一般的であったが,一般的に軽度であった.
結論:
- ガバペンチン (gabapentin) は,耐性慢性咳に対する効果的でよく耐える治療法です.
- 結果は,関連するメカニズムとして中央反射感受性を支持する.
- ガバペンチンは,この衰弱状態に対する新しい治療の選択肢を提供します.
関連する概念動画
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...